Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Viridian Therapeutics Inc.

Viridian Therapeutics ( ($VRDN) ) just unveiled an update. On May 24, 2026, Viridian Therapeutics, Inc. entered into a Commercial Manufacturing Ser...

Viridian Therapeutics secures WuXi deal for veligrotug manufacturing

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Viridian Therapeutics today and set a price target of $26.00. Clark-Gartner cov...

Evercore ISI Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)

Viridian Therapeutics ( ($VRDN) ) has shared an announcement. On May 11, 2026, Viridian Therapeutics completed a $250 million public offering of 1....

Viridian Therapeutics Raises $359 Million in Offerings

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Context Therapeutics (CN...

Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biodesix (BDSX), Viridian Therapeutics (VRDN) and Ab...

Analysts Are Bullish on These Healthcare Stocks: Biodesix (BDSX), Viridian Therapeutics (VRDN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ufp Technologies (UFPT), Viridian Therapeutics (VRDN...

Analysts Are Bullish on These Healthcare Stocks: Ufp Technologies (UFPT), Viridian Therapeutics (VRDN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Henry Schein (HSIC), Viridian Therapeutics (VRDN) and Q32 Bio (QT...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Henry Schein (HSIC), Viridian Therapeutics (VRDN) and Q32 Bio (QTTB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AptarGroup (ATR) and Viridian Therapeutics (VRDN). AptarGroup (AT...

Market Cap	$1.59B	P/E Ratio	N/A
52W High	$34.29	52W Low	$13.18
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	6.4%	52W Position	18.1%
Overall Score	36	Value Score	60
Quality Score	23	Technical Score	27

EPS Current Est	$-3.71	EPS Next Est	$-2.4
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRDN	$17.00	-1.39%	1.49M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRDN	$17.00	-1.4%	1.49M
3
4
5
6

VRDN

VRDN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Viridian Therapeutics Inc. Data in Excel

Get Viridian Therapeutics Inc. Data in Excel